Catalogue Search | MBRL
Search Results Heading
Explore the vast range of titles available.
MBRLSearchResults
-
DisciplineDiscipline
-
Is Peer ReviewedIs Peer Reviewed
-
Item TypeItem Type
-
SubjectSubject
-
YearFrom:-To:
-
More FiltersMore FiltersSourceLanguage
Done
Filters
Reset
70
result(s) for
"Pahlman, L."
Sort by:
Risk of bacteremia in patients presenting with shaking chills and vomiting - a prospective cohort study
2020
Chills and vomiting have traditionally been associated with severe bacterial infections and bacteremia. However, few modern studies have in a prospective way evaluated the association of these signs with bacteremia, which is the aim of this prospective, multicenter study. Patients presenting to the emergency department with at least one affected vital sign (increased respiratory rate, increased heart rate, altered mental status, decreased blood pressure or decreased oxygen saturation) were included. A total of 479 patients were prospectively enrolled. Blood cultures were obtained from 197 patients. Of the 32 patients with a positive blood culture 11 patients (34%) had experienced shaking chills compared with 23 (14%) of the 165 patients with a negative blood culture, 𝑃 = 0.009. A logistic regression was fitted to show the estimated odds ratio (OR) for a positive blood culture according to shaking chills. In a univariate model shaking chills had an OR of 3.23 (95% CI 1.35–7.52) and in a multivariate model the OR was 5.9 (95% CI 2.05–17.17) for those without prior antibiotics adjusted for age, sex, and prior antibiotics. The presence of vomiting was also addressed, but neither a univariate nor a multivariate logistic regression showed any association between vomiting and bacteremia. In conclusion, among patients at the emergency department with at least one affected vital sign, shaking chills but not vomiting were associated with bacteremia.
Journal Article
A population-based comparison of the survival of patients with colorectal cancer in England, Norway and Sweden between 1996 and 2004
2011
ObjectiveTo examine differences in the relative survival and excess death rates of patients with colorectal cancer in Norway, Sweden and England.MethodsAll individuals diagnosed with colorectal cancer (ICD10 (International Classification of Diseases, 10th revision) C18–C20) between 1996 and 2004 in England, Norway and Sweden were included in this population-based study of patients with colorectal cancer. The main outcome measures were 5-year cumulative relative period of survival and excess death rates stratified by age and period of follow-up.ResultsThe survival of English patients with colorectal cancer was significantly lower than was observed in both Norway and Sweden. Five-year age-standardised colon cancer relative survival was 51.1% (95% CI 50.1% to 52.0%) in England compared with 57.9% (95% CI 55.2% to 60.5%) in Norway and 59.9% (95% CI 57.7% to 62.0%) in Sweden. Five-year rectal cancer survival was 52.3% (95% CI 51.1% to 53.5%) in England compared with 60.7% (95% CI 57.0% to 64.2%) and 59.8% (95% CI 56.9% to 62.6%) in Norway and Sweden, respectively. The lower survival for colon cancer in England was primarily due to a high number of excess deaths among older patients in the first 3 months after diagnosis. In patients with rectal cancer, excess deaths remained elevated until 2 years of follow-up. If the lower excess death rate in Norway applied in the English population, then 890 (13.6%) and 654 (16.8%) of the excess deaths in the colon and rectal cancer populations, respectively, could have been prevented at 5 years follow-up. Most of these avoidable deaths occurred shortly after diagnosis.ConclusionsThere was significant variation in survival between the countries, with the English population experiencing a poorer outcome, primarily due to a relatively higher number of excess deaths in older patients in the short term after diagnosis. It seems likely, therefore, that in England a greater proportion of the population present with more rapidly fatal disease (especially in the older age groups) than in Norway or Sweden.
Journal Article
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
by
Wiggers, Theo
,
Marijnen, Corrie A.M
,
Putter, Hein
in
Adenocarcinoma - mortality
,
Adenocarcinoma - radiotherapy
,
Adenocarcinoma - surgery
2001
More than 1800 patients with rectal cancer underwent total mesorectal excision either alone or after preoperative radiotherapy.
Local recurrence is a serious problem in the treatment of rectal cancer, since it causes disabling symptoms and is difficult to treat.
1
,
2
There is a high incidence of local recurrence (15 to 45 percent) after conventional surgery, in which blunt dissection of the rectal fascia often fails to remove all the tissue that may bear tumor.
3
–
5
In an attempt to improve local control and survival after conventional surgery, radiotherapy has been given. The only randomized trial that compared preoperative and postoperative radiotherapy showed the superiority of preoperative radiotherapy for local control.
6
The Swedish Rectal Cancer Trial found that . . .
Journal Article
Persistent Aspergillus fumigatus infection in cystic fibrosis: impact on lung function and role of treatment of asymptomatic colonization—a registry-based case–control study
by
Al Shakirchi, Mahasin
,
Svedberg, Marcus
,
Påhlman, Lisa I.
in
Antibiotics
,
Antifungal
,
Antifungal agents
2022
Background
Aspergillus fumigatus
is the most common filamentous fungus isolated from the airways of people with cystic fibrosis (CF). The aim of this study was to investigate how chronic
A. fumigatus
colonization affects lung function in people with CF, to identify risk factors for colonization, and to evaluate antifungal treatment of asymptomatic
Aspergillus
colonization.
Methods
Data from 2014–2018 was collected from the Swedish CF registry and medical records. Baseline data before the start of
A. fumigatus
colonization was compared with the two succeeding years to evaluate how colonization and treatment affected lung function and other clinical aspects.
Results
A total of 437 patients were included, of which 64 (14.6%) became colonized with
A. fumigatus
during the study period. Inhaled antibiotics was associated with
A. fumigatus
colonization (adjusted OR 3.1, 95% CI 1.6–5.9,
p
< 0.05). Fungal colonization was not associated with a more rapid lung function decline or increased use of IV-antibiotics compared to the non-colonized group, but patients with
A. fumigatus
had more hospital days, a higher increase of total IgE, and higher eosinophil counts. In the
Aspergillus
group, 42 patients were considered to be asymptomatic. Of these, 19 patients received antifungal treatment. Over the follow up period, the treated group had a more pronounced decrease in percent predicted Forced Expiratory Volume in one second (ppFEV1) compared to untreated patients (− 8.7 vs − 1.4 percentage points,
p
< 0.05).
Conclusion
Inhaled antibiotics was associated with
A. fumigatus
colonization, but no association was found between persistent
A. fumigatus
and subsequent lung function decline. No obvious benefits of treating asymptomatic
A. fumigatus
colonization were demonstrated.
Journal Article
Respiratory adenovirus infections in immunocompetent and immunocompromised adult patients
2019
Adenovirus (AdV) can cause severe respiratory infections in children and immunocompromised patients, but less is known about severe AdV pneumonia in immunocompetent adults. In this retrospective study, we compared respiratory tract infections and pneumonia caused by AdV in immunocompromised and immunocompetent adult patients regarding clinical presentation and severity of infection. The results show that AdV can cause severe infections in both immunocompetent and immunocompromised patients, and the clinical presentation and need for hospitalisation, mechanical ventilation and antiviral treatment were equal in both groups. No underlying risk factors for severe AdV infection in healthy individuals were identified.
Journal Article
Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer
2011
Background:
Growth differentiation factor 15 (GDF15) belongs to the transforming growth factor beta superfamily and has been associated with activation of the p53 pathway in human cancer. The aim of this study was to assess the prognostic value of GDF15 in patients with colorectal cancer (CRC).
Methods:
Immunohistochemistry and tissue microarrays were used to analyse GDF15 protein expression in 320 patients with CRC. In a subgroup of 60 patients, the level of GDF15 protein in plasma was also measured using a solid-phase proximity ligation assay.
Results:
Patients with CRC with moderate to high intensity of GDF15 immunostaining had a higher recurrence rate compared with patients with no or low intensity in all stages (stages I–III) (HR, 3.9; 95% CI, 1.16–13.15) and in stage III (HR, 10.32; 95% CI, 1.15–92.51). Patients with high plasma levels of GDF15 had statistically shorter time to recurrence (
P
=0.041) and reduced overall survival (
P
=0.002).
Conclusion:
Growth differentiation factor 15 serves as a negative prognostic marker in CRC. High expression of GDF15 in tumour tissue and high plasma levels correlate with an increased risk of recurrence and reduced overall survival.
Journal Article
Swedish Experience with Peritonectomy and HIPEC. HIPEC in Peritoneal Carcinomatosis
2008
Background
Peritonectomy with heated intraperitoneal chemotherapy (HIPEC) has shown a survival benefit in selected patients with peritoneal carcinomatosis. This prospective non-randomized study was designed to identify factors associated with postoperative morbidity and survival after peritonectomy HIPEC in patients with this condition.
Method
Data were prospectively collected from all patients with peritoneal carcinomatosis treated by means of peritonectomy and HIPEC at Uppsala University Hospital between October 2003 and September 2006. Depending on the primary tumor, mitomycin C or a platinum compound was used as a chemotherapeutic agent for perfusion.
Results
A total of 103 patients were treated. Primary tumors were pseudomyxoma peritonei (47 patients), colorectal cancer (38 patients), gastric cancer (6 patients), ovarian cancer (6 patients) and mesothelioma (5 patients). Postoperative morbidity was 56.3% and was significantly lower in patients treated with mitomycin C for pseudomyxoma peritonei (42%) than in those with another diagnosis treated with platinum compound (71%,
P
< 0.05). Postoperative mortality was less than 1%. At 2 years, overall survival was estimated to be 72.3%, and disease-free survival was 33.5%. Factors influencing overall and disease-free survival were tumor type and optimal cytoreduction.
Conclusion
Postoperative morbidity is dependent mainly on a tumor type; however, the chemotherapeutic agent used might also influence morbidity. Survival is determined by optimal cytoreduction and tumor type. Irrespective of age, patients with good performance status benefit from this treatment.
Journal Article
Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion
by
Påhlman, L.
,
Wallin, I.
,
Mahteme, H.
in
Abdomen
,
Adult
,
Antineoplastic Agents - administration & dosage
2008
Objective
To evaluate the perfusate and systemic kinetics of oxaliplatin during hyperthermic intraperitoneal chemotherapy (HIPEC) using a selective analytical technique.
Methods
HIPEC was carried out in eight patients by the open abdomen coliseum technique for 30 min at 41.5-43°C with an average of 427 mg/m
2
of oxaliplatin in 5% dextrose solution. Blood and perfusate samples were collected during the perfusion. Additional blood samples were taken up to 2 h after the end of perfusion. The analysis was performed by liquid chromatography and post-column derivatization with N,N-diethyldithiocarbamate using microwave heating.
Results
The mean elimination half-life of oxaliplatin in the perfusate was 29.5 min (range 21.1-41.2 min) and in the peripheral circulation 24.7 min (range 21.7-27.7 min). The ratio of the areas under the time concentration curve in perfusate and blood was 12.8 ± 2.9.
Conclusion
The systemic exposure of oxaliplatin measured after HIPEC using a selective analytical technique is considerably lower than previously reported results obtained by atomic absorption spectroscopy.
Journal Article
Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer – the RAPIDO trial
by
Wiggers, Theo
,
Marijnen, Corrie AM
,
Blomqvist, Lennart
in
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
,
Biomedical and Life Sciences
,
Biomedicine
2013
Background
Current standard for most of the locally advanced rectal cancers is preoperative chemoradiotherapy, and, variably per institution, postoperative adjuvant chemotherapy. Short-course preoperative radiation with delayed surgery has been shown to induce tumour down-staging in both randomized and observational studies. The concept of neo-adjuvant chemotherapy has been proven successful in gastric cancer, hepatic metastases from colorectal cancer and is currently tested in primary colon cancer.
Methods and design
Patients with rectal cancer with high risk features for local or systemic failure on magnetic resonance imaging are randomized to either a standard arm or an experimental arm. The standard arm consists of chemoradiation (1.8 Gy x 25 or 2 Gy x 25 with capecitabine) preoperatively, followed by selective postoperative adjuvant chemotherapy. Postoperative chemotherapy is optional and may be omitted by participating institutions. The experimental arm includes short-course radiotherapy (5 Gy x 5) followed by full-dose chemotherapy (capecitabine and oxaliplatin) in 6 cycles before surgery. In the experimental arm, no postoperative chemotherapy is prescribed. Surgery is performed according to TME principles in both study arms. The hypothesis is that short-course radiotherapy with neo-adjuvant chemotherapy increases disease-free and overall survival without compromising local control. Primary end-point is disease-free survival at 3 years. Secondary endpoints include overall survival, local control, toxicity profile, and treatment completion rate, rate of pathological complete response and microscopically radical resection, and quality of life.
Discussion
Following the advances in rectal cancer management, increased focus on survival rather than only on local control is now justified. In an experimental arm, short-course radiotherapy is combined with full-dose chemotherapy preoperatively, an alternative that offers advantages compared to concomitant chemoradiotherapy with or without postoperative chemotherapy. In a multi-centre setting this regimen is compared to current standard with the aim of improving survival for patients with locally advanced rectal cancer.
Trial registration
ClinicalTrials.gov
NCT01558921
Journal Article
Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial
2005
The safety and short-term benefits of laparoscopic colectomy for cancer remain debatable. The multicentre COLOR (COlon cancer Laparoscopic or Open Resection) trial was done to assess the safety and benefit of laparoscopic resection compared with open resection for curative treatment of patients with cancer of the right or left colon.
627 patients were randomly assigned to laparoscopic surgery and 621 patients to open surgery. The primary endpoint was cancer-free survival 3 years after surgery. Secondary outcomes were short-term morbidity and mortality, number of positive resection margins, local recurrence, port-site or wound-site recurrence, metastasis, overall survival, and blood loss during surgery. Analysis was by intention to treat. Here, clinical characteristics, operative findings, and postoperative outcome are reported.
Patients assigned laparoscopic resection had less blood loss compared with those assigned open resection (median 100 mL [range 0–2700]
vs 175 mL [0–2000], p<0·0001), although laparoscopic surgery lasted 30 min longer than did open surgery (p<0·0001). Conversion to open surgery was needed for 91 (17%) patients undergoing the laparoscopic procedure. Radicality of resection as assessed by number of removed lymph nodes and length of resected oral and aboral bowel did not differ between groups. Laparoscopic colectomy was associated with earlier recovery of bowel function (p<0·0001), need for fewer analgesics, and with a shorter hospital stay (p<0·0001) compared with open colectomy. Morbidity and mortality 28 days after colectomy did not differ between groups.
Laparoscopic surgery can be used for safe and radical resection of cancer in the right, left, and sigmoid colon.
Journal Article